在COVID-19中使用抗凝固药疗法:叙述性审查
Zeinab Mohseni Afshar1, Ali Tavakoli Pirzaman2, Rezvan Hosseinzadeh2
1Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Clinical and translational science
|June 16, 2023
概括
COVID-19 (冠状病毒疾病2019) 可能导致危险的血栓 (血栓形成) 和高凝血状态,特别是在严重的情况下. 抗凝剂治疗对于在SARS-CoV-2感染患者中管理这些危及生命的并发症至关重要.
科学领域:
- 内部医学 内部医学
- 传染性疾病 传染性疾病
- 血液学 血液学 血液学
背景情况:
- 冠状病毒疾病2019 (COVID-19),由SARS-CoV-2引起,呈现出各种临床表现,包括凝血病和血栓形成.
- 动脉和静脉血栓事件是COVID-19的重要并发症,特别是在住院和重症患者中.
- 这些血栓事件导致严重的结果,包括神经和心脏事件,源于病毒诱导的高凝血状态.
研究的目的:
- 审查COVID-19相关高凝血的病理生理学.
- 分析抗凝固药治疗在治疗SARS-CoV-2感染中的作用和疗效.
- 讨论在不同患者群体中使用抗凝剂的优缺点.
主要方法:
- 文献综述侧重于COVID-19,高凝血性和血栓形成.
- 对将SARS-CoV-2感染与凝血障碍联系起来的病理生理机制的分析.
- 关于COVID-19患者抗凝剂治疗策略的证据综合.
主要成果:
- COVID-19引发严重的高凝血状态,这是严重疾病和血栓性并发症的主要驱动因素.
- 血栓形成,包括静脉血栓栓塞和动脉事件,是SARS-CoV-2感染的频繁而严重的表现.
- 抗凝剂被确定为减轻COVID-19相关的血栓形成风险的关键疗法.
结论:
- 在COVID-19中高凝血状态需要仔细考虑抗凝剂治疗.
- 抗凝剂的使用是管理严重COVID-19的关键策略,平衡利益与潜在风险.
- 需要进一步的研究,以优化各种COVID-19患者亚组的抗凝剂协议.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care
11
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
11
Anticoagulant Drugs: Low-Molecular-Weight Heparins
767
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
767
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
15
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
15
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
16
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
16
Pulmonary Embolism I: Introduction
10
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
10


